News Flex Pharma Shifts Focus to Programs Targeting MS, Other Neurological Diseases Flex Pharma Shifts Focus to Programs Targeting MS, Other Neurological Diseases by Patricia Silva, PhD | January 26, 2017 Share this article: Share article via email Copy article link Flex PharmaĀ said it plans toĀ prioritize developing its clinical programs in neurological diseases, including multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), and peripheral neuropathies like Charcot-Marie Tooth (CMT). One or two proof-of-concept, Phase 2 clinical trials are planned for this year in the United States to evaluate Flex Pharmaās transient receptor potential (TRP) ion channel activator, FLX-787. The drug isĀ capable of interfering with TRPV1 and TRPA1 receptors involved in pain and neurogenic inflammation, the company reported. āIn 2017, we expect to have multiple Phase 2 studies ongoing with our single agent candidate, FLX-787, with results from our MS study towards the end of the year,ā Thomas Wessel, MD, PhD, Flex Pharmaās chief medical officer, said in a press release. The company enrolled a group of MS and ALS patients last year in two exploratory Phase 2 studies in Australia. The randomized, placebo-controlled, cross-over studies were designed to assess FLX-787’s safety and effectiveness in patients with cramps and spasticity linked to their disease. Results from the MS study are expected this year. āBy prioritizing our clinical programs to severe neurological diseases ahead of nocturnal leg cramps, we can focus on those patients with the greatest unmet need and accelerate our research efforts for cramps and spasticity,ā Wessel said. Spasticity refers to feelings of stiffness and involuntary muscle spasms. It is one of the most common symptoms of MS, and itĀ can vary from mild discomfort to severe, painful, uncontrollable spasms, usually in the legs. Spasticity can be aggravated by sudden movements, temperature changes, infections, or tight clothing. Left untreated, it can lead to serious complications, including contractures (frozen or immobilized joints)Ā and pressure sores. āWe believe that topical Chemical Neuro Stimulation, the process whereby small molecules activate TRP ion channels on sensory nerves in the oral mucosa, triggers a reflex response to inhibit the hyper excitable motor neurons in the spinal cord and reduce muscle cramps,ā said Rod MacKinnon, MD, Flex Pharma co-founder and a Nobel Prize winner. āOur approach has a broad range of applications that we believe will ultimately benefit the millions of people that suffer from frequent painful muscle cramps.ā Print This Page About the Author Patricia Silva, PhD PatrĆcia holds a PhD in medical microbiology and infectious diseases from the Leiden University Medical Center, Netherlands, and completed a postdoctoral research fellowship at the Instituto de Medicina Molecular, Lisbon, Portugal. Her work in academia was mainly focused on molecular biology and the genetic traits of infectious agents such as viruses and parasites. PatrĆcia earned several travel awards to present her work at international scientific meetings. She is a published author of several peer-reviewed science articles. Tags ALS, clinical trial, Flex Pharma, neurological diseases, spasticity
April 19, 2024 News by Lindsey Shapiro, PhD AAN 2024: Long-term data support early Kesimpta start in relapsing MS
April 18, 2024 Columns by Benjamin Hofmeister Learning how to write a ‘SOAP’ note feels different after an MS diagnosis
April 18, 2024 News by Marisa Wexler, MS AAN 2024: Sustained myelin, nerve cell gains with long-term CNM-Au8